Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLY-1 phase 2 study of DAY101 in pediatric recurrent or progressive low-grade glioma with activating BRAF alteration
MOH_2021-05-27_009743Phase 2Recruiting
- Sponsor
- DOT Therapeutics-1 Inc. (Day One)
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tovorafenib in childhood low-grade glioma (pLGG), sponsored by DOT Therapeutics-1 Inc. (Day One). Started May 2021; status: recruiting.
02
Drugs
tovorafenib
03
Conditions
childhood low-grade glioma (pLGG)
Beyond the preview
Go deeper on MOH_2021-05-27_009743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-27_009743.